U.S. Markets open in 5 hrs 12 mins

Panaxia Labs Israel Ltd (PNAX.TA)

Tel Aviv - Tel Aviv Delayed Price. Currency in ILA
Add to watchlist
137.90-1.10 (-0.79%)
At close: 5:24PM IDT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close139.00
Open143.00
Bid149.30 x N/A
Ask153.50 x N/A
Day's Range149.30 - 157.80
52 Week Range137.90 - 322.00
Volume74,585
Avg. Volume127,927
Market Cap20.204B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.86
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJun 03, 2012
1y Target EstN/A
  • PR Newswire

    Panaxia continues growth: sums up 1st half of 2021 with 37.3 million revenues, 38.4% growth in comparison to 2020

    The Israeli subsidiary of Panaxia Global, Panaxia Labs Israel Ltd. ("Panaxia Israel"), (TASE: PNAX), a global pharma company that develops, manufactures and markets progressive medical cannabis products in pharmaceutical quality, published today its financial reports for the second quarter and first half of 2021.

  • PR Newswire

    Panaxia and Neuraxpharm Expands Strategic Collaboration to Poland

    Panaxia Labs Israel Ltd. ("Panaxia Israel"), (TASE: PNAX), a global pharma company, specializes in developing, manufacturing and marketing advanced medical cannabis products in pharmaceutical quality and its partner, Neuraxpharm, Europe's leading Pharma Company focused on the treatment of Central Nervous System (CNS) disorders, announced today expanding their strategic collaboration into the Polish market. The companies signed an exclusive agreement to the manufacture, commercialization, and dis

  • PR Newswire

    Panaxia & AxioNovo GmbH will market cannabis-based products in Germany

    Panaxia Labs Israel Ltd. ("Panaxia Israel"), (TASE: PNAX), a global pharma company, specializes in developing, manufacturing and marketing progressive medical cannabis products in pharmaceutical quality and the German pharmaceutical company AxioNovo GmbH, specialized in the field of Oncology, announced today the signing of an agreement. The agreement, a part of Panaxia's collaboration with Neuraxpharm, is for the marketing, sale and distribution of a new series of medical cannabis products, with